全文获取类型
收费全文 | 1118263篇 |
免费 | 77596篇 |
国内免费 | 4936篇 |
专业分类
耳鼻咽喉 | 15302篇 |
儿科学 | 35002篇 |
妇产科学 | 29081篇 |
基础医学 | 158773篇 |
口腔科学 | 30257篇 |
临床医学 | 101494篇 |
内科学 | 210373篇 |
皮肤病学 | 24952篇 |
神经病学 | 83900篇 |
特种医学 | 44846篇 |
外国民族医学 | 224篇 |
外科学 | 167198篇 |
综合类 | 29288篇 |
现状与发展 | 16篇 |
一般理论 | 270篇 |
预防医学 | 77240篇 |
眼科学 | 25908篇 |
药学 | 90925篇 |
88篇 | |
中国医学 | 5631篇 |
肿瘤学 | 70027篇 |
出版年
2021年 | 10123篇 |
2019年 | 9381篇 |
2018年 | 13022篇 |
2017年 | 10386篇 |
2016年 | 11518篇 |
2015年 | 13375篇 |
2014年 | 17840篇 |
2013年 | 24484篇 |
2012年 | 33913篇 |
2011年 | 36091篇 |
2010年 | 21266篇 |
2009年 | 19632篇 |
2008年 | 32353篇 |
2007年 | 34535篇 |
2006年 | 35086篇 |
2005年 | 33542篇 |
2004年 | 31147篇 |
2003年 | 29844篇 |
2002年 | 28599篇 |
2001年 | 61025篇 |
2000年 | 62529篇 |
1999年 | 52078篇 |
1998年 | 13209篇 |
1997年 | 11789篇 |
1996年 | 11621篇 |
1995年 | 10879篇 |
1994年 | 9850篇 |
1993年 | 9156篇 |
1992年 | 38148篇 |
1991年 | 36563篇 |
1990年 | 36016篇 |
1989年 | 34512篇 |
1988年 | 31078篇 |
1987年 | 30175篇 |
1986年 | 28357篇 |
1985年 | 26554篇 |
1984年 | 19233篇 |
1983年 | 16148篇 |
1982年 | 8839篇 |
1979年 | 17038篇 |
1978年 | 11404篇 |
1977年 | 10229篇 |
1976年 | 8837篇 |
1975年 | 10068篇 |
1974年 | 11651篇 |
1973年 | 11273篇 |
1972年 | 10754篇 |
1971年 | 10092篇 |
1970年 | 9252篇 |
1969年 | 8938篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
3.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
4.
目的 鉴定当地民间应用普遍的野生药用真菌,并探讨其治疗肿瘤的作用机制。方法 采用形态学和分子生物学方法对一株采自定陶仿山野生药用真菌进行鉴定,确定为硬皮马勃。通过文献检索收集硬皮马勃化学成分,利用PubChem软件和TCMSP、GCS数据库得到化学成分结构信息及其药用动力学参数和相关靶点分析,通过SysDT和WES系统鉴定潜在化学成分靶点,利用CTD数据库获得靶点功能,将潜在化合物和肿瘤相关靶点导入Cytoscape3.8.0软件构建分子-靶标网络。应用DAVID数据库对肿瘤相关靶点进行GO和KEGG富集分析,揭示有关活性成分靶点所涉及的生物学过程和通路,将肿瘤相关靶点和通路导入Cytoscape3.8.0软件构建靶点-通路网络。结果 从文献中获得硬皮马勃的化学成分59个,通过ADME计算系统筛选出5个潜在活性的化合物即活性成分,预测到38个靶点,其中与肿瘤相关靶点16个。这些活性成分主要通过Toll-like receptor、PI3K-AKT、MAPK和NF-kappa B等通路参与免疫应答,抑制肿瘤细胞生长、增殖,促进其凋亡。结论 表明硬皮马勃治疗肿瘤具有多靶点、多途径协同作用的特点,并通过多层次效应达到治疗肿瘤的效果。本研究为更好理解硬皮马勃作用肿瘤的机制和肿瘤药物开发提供理论依据。 相似文献
5.
ObjectiveEach pulmonary segment is an anatomical and functional unit. However, it is fundamentally difficult to precisely distinguish every pulmonary segment using the conventional pulmonary intersegmental planes from computed tomography images. Building arteriopulmonary segments is likely to be an effective way to identify pulmonary segments.MethodsThe thoracic computed tomography images of 40 patients were collected. The anatomic structures of interest were extracted in the transverse, sagittal, and coronal planes using the semi-automated segmentation tools provided by Amira software. The intrapulmonary vessels were subsequently segmented and reconstructed. The distributions of the pulmonary arteries, veins, and bronchi were observed. In patients with pulmonary masses, the mass was also reconstructed.ResultsThe three-dimensional reconstructed images showed the branches of the pulmonary artery ramified up to their eighth order covering the entire lung as well as evident intersegmental gaps without pulmonary arteries. The segmental artery was closely accompanied by the segmental bronchi in 486 pulmonary segments (90% of total number of segments). The size and spatial location of the pulmonary mass within a pulmonary segment were also clearly visible.ConclusionsDemarcation of arteriopulmonary segments can be used to precisely distinguish every pulmonary segment and provide its detailed anatomical structure before pulmonary segmentectomy. 相似文献
6.
7.
8.
9.
10.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献